Share this Page:
A recent study published in Clinical Genitourinary Cancer has found that the use of first-line sunitinib did not have any influence on the effectiveness of second-line immunotherapy for patients with metastatic renal cell carcinoma (RCC).
The researchers found no statistically significant association between the duration of the use of first-line sunitinib and clinical outcomes with second-line immunotherapy. Patients receiving first-line sunitinib for more than 6 months had better overall survival than patients who used sunitinib for less than 6 months. In conclusion, their findings support the fact that previous therapy does not influence the effectiveness of subsequent immunotherapy.
